CD274 and non-small cell lung carcinoma: Furthermore, as the use of ICIs in the first line is rapidly changing the treatment scenario for advanced NSCLC, robust predictive biomarkers might prove critical for therapeutic decisions, especially in the case of reliable negative predictive factors, which may potentially allow to select those patients who do not benefit from the use of an ICI in addition or in place of platinum-based chemotherapy in first line, irrespective of PD-L1 expression.